MV-4-11 Xenograft Model Service for AML

The MV-4-11 cell line serves as a clinically relevant in vivo model for acute myeloid leukemia (AML), particularly for studying therapeutic responses in FLT3-ITD mutated malignancies. As a specialized pre-clinical contract research organization, Alfa Cytology delivers a comprehensive, turnkey MV-4-11 Xenograft Model Service that combines high-precision cell handling with standardized in vivo protocols to drive your oncology drug discovery pipeline forward.

Overview of MV-4-11 Xenograft Model for AML

The MV-4-11 xenograft model is an established and extensively characterized in vivo translational platform widely utilized in hematological research, specifically for AML. By transplanting human MV-4-11 myelomonocytic leukemia cells into immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow engraftment, and pathological progression seen in clinical leukemia patients.

Biologically, the MV-4-11 model is highly valued for its stable expression of the FLT3-ITD mutation, which makes it a benchmark system for evaluating targeted FLT3 inhibitors, as well as broader classes of antileukemic agents. The model preserves key human myeloid molecular signatures, including distinct signaling pathways that regulate blast proliferation and survival. Consequently, the MV-4-11 model is frequently employed in pre-clinical screening to assess the anti-tumor potency of small-molecule inhibitors, targeted monoclonal antibodies, and combination therapeutic regimens, providing a robust experimental window for longitudinal efficacy studies.

Fig 1. Schematic of MV-4-11 xenograft model. (Christodoulou I, et al., 2021)

Cell Line Information: MV-4-11

The MV-4-11 cell line was established from the peripheral blood of a patient diagnosed with biphenotypic B-myelomonocytic leukemia. Under standard in vitro conditions, it grows as a suspension culture and is widely recognized for its genetic stability and clinical relevance in myeloid oncology.

Our Services

Workflow of MV-4-11 Xenograft Model Construction

• Cell Culture & Quality Control: Human MV-4-11 cells are expanded in vitro using certified growth media under strictly optimized parameters. STR profiling and mycoplasma clearance verification are performed prior to harvesting to ensure absolute biological purity and phenotypic identity.
• Host Selection & Acclimatization: Standardized, healthy immunocompromised mice are sourced from validated vendors. Animals undergo a dedicated acclimatization phase to establish stable baseline physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability MV-4-11 cells is prepared in a sterile physiological buffer. The cells are precisely inoculated in vivo into rodent cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, leukemic progression is systematically monitored using FACS to detect human CD45+ or specific myeloid markers in peripheral blood samples. Animal body weights, physical baselines, and general behavioral health are routinely documented.
• Stratification & Dosing: When systemic leukemic burden reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts. This stratification step ensures balanced baseline dimensions across all groups before customized therapeutic dosing regimens commence.

Fig 2. MV-4-11 Xenograft Model Construction Workflow

Case Study - MV-4-11 Xenograft Model Development

A pre-clinical validation study was conducted utilizing the MV-4-11 xenograft model to evaluate the therapeutic efficacy of a novel FLT3-targeted small-molecule inhibitor in AML. Following precision intravenous inoculation of human MV-4-11 cells into immunodeficient mice, the animals demonstrated steady, systemic engraftment and a highly predictable disease progression profile across all study cohorts. Subjects assigned to the active treatment group exhibited a significant reduction in circulating leukemic blasts and prolonged survival compared to the vehicle control group, confirming the model's sensitivity and predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing our MV-4-11 platform, please reach out to us today to discuss your project layout with our scientific team.

For research use only. Not intended for any clinical use.